Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy
Gothenburg, November 9, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that it has entered into an agreement with BioNTech for contract manufacturing regarding viral vectors for the company's CAR T-cell therapy, ELC-401.BioNTech IMFS is a contract development and manufacturing organization in Germany that specializes in the industrialization of cell and gene therapies such as virus vectors and cell products. Elicera Therapeutics has entered into an